Clinical Trials
57 trialsCAN3001
Janssen Research & Development, LLC
CINC424A2X01B Rollover Protocol
Novartis
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis
ASC4INDIA
Novartis
AGAVE-201
Syndax Pharmaceuticals
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
Hope Biosciences Research Foundation
REACH 5
Novartis
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Pharmacyclics LLC.
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Hope Biosciences Research Foundation
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Novartis
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
Sanofi
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd.
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
Genentech, Inc.
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Alexion Pharmaceuticals, Inc.
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Pfizer
Phase I Study of Milatuzumab for Graft Versus Host Disease
Gilead Sciences
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
DIALOG
Novartis
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
Novartis
RESONATEâ„¢
Pharmacyclics LLC.
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
A Study in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Pharmacyclics LLC.
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Pfizer
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
MetrioPharm AG
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Novartis
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain
Mundipharma Research GmbH & Co KG
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
GlaxoSmithKline
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
Hoffmann-La Roche
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
Bristol-Myers Squibb
To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain
Mundipharma Research GmbH & Co KG
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Gilead Sciences
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Hoffmann-La Roche
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Bristol-Myers Squibb
LASOR
Novartis
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Pfizer
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Mirati Therapeutics Inc.
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer